Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer J. 2021 Feb 1;11(2):25. doi: 10.1038/s41408-021-00410-w.

Authors

Abhishek Maiti^#¹, Courtney D DiNardo^#¹, Naval G Daver¹, Caitlin R Rausch², Farhad Ravandi¹, Tapan M Kadia¹, Naveen Pemmaraju¹, Gautam Borthakur¹, Prithviraj Bose¹, Ghayas C Issa¹, Nicholas J Short¹, Musa Yilmaz¹, Guillermo Montalban-Bravo¹, Alessandra Ferrajoli¹, Elias J Jabbour¹, Nitin Jain¹, Maro Ohanian¹, Koichi Takahashi¹, Philip A Thompson¹, Sanam Loghavi³, Kathryn S Montalbano¹, Sherry Pierce¹, William G Wierda¹, Hagop M Kantarjian¹, Marina Y Konopleva⁴

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mkonople@mdanderson.org.

^# Contributed equally.

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, N.I.H., Extramural

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Decitabine / therapeutic use*
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Male
Middle Aged
Mutation / drug effects
Protein Kinase Inhibitors / therapeutic use*
Sulfonamides / therapeutic use*
Treatment Outcome
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors*
fms-Like Tyrosine Kinase 3 / genetics

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Protein Kinase Inhibitors
Sulfonamides
Decitabine
FLT3 protein, human
fms-Like Tyrosine Kinase 3
venetoclax

Grants and funding